Characteristics of Patients with Hereditary Angioedema Who Reduced Lanadelumab Treatment Administration Frequency: A Retrospective Observational Study of US Claims Data
This real-world analysis suggests that patients with less frequent hereditary angioedema-related healthcare encounters, lower disease activity, and lower costs within 6 months before lanadelumab initiation are more likely to achieve reduced dosing frequency.
Authors
- Nicole Princic (ORCID: https://orcid.org/0000-0003-3127-4365)
- Bob G. Schultz (ORCID: https://orcid.org/0000-0002-7023-8378)
- Krystal Sing
- Chintal H. Shah (ORCID: https://orcid.org/0000-0002-0225-507X)
- Salomé Juethner
- Kristin Evans (ORCID: https://orcid.org/0000-0003-0987-1745)
Institutions
- University of Maryland, Baltimore (US)
- Takeda (United States) (US)
- Takeda (Japan) (JP)
Publication Details
- Journal
- Drugs - Real World Outcomes
- Published
- 2025-01-29
- DOI
- https://doi.org/10.1007/s40801-024-00470-x
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Takeda Pharmaceuticals U.S.A.